Biosimilar approvals on the rise after a two-year slump — Amgen report
Amgen estimates that biosimilars resulted in $3.2 billion in savings last quarter alone, according to its latest trend report. And though the last two years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
